Autosomal dominant Charcot-Marie-Tooth disease type 2

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:64746
Who is this for?
Show terms as
2Active trials2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Autosomal dominant Charcot-Marie-Tooth disease type 2 (also called CMT2 or hereditary motor and sensory neuropathy type 2, HMSN II) is a inherited nerve disease that affects the peripheral nervous system — the nerves outside the brain and spinal cord. Unlike the more common CMT type 1, which damages the protective myelin sheath around nerves, CMT2 directly damages the nerve fibers themselves (called axons). This means signals between the brain and the muscles and skin travel poorly or not at all. The disease mainly affects the legs and arms, causing muscle weakness and wasting, especially in the lower legs and feet. People often notice foot deformities like high arches (pes cavus) or hammer toes. Numbness, tingling, and reduced ability to feel pain, heat, or cold are also common. Symptoms usually begin in the teens or early adulthood, though this varies widely. There is currently no cure for CMT2. Treatment focuses on managing symptoms, maintaining mobility through physical and occupational therapy, and using assistive devices like braces or orthotics. Pain management and regular monitoring by a neurologist are important parts of care. Most people with CMT2 have a normal life expectancy, though the disease can significantly affect quality of life and independence over time.

Also known as:

Key symptoms:

Muscle weakness in the lower legs and feetMuscle wasting (shrinking) in the lower legs, giving a 'stork leg' appearanceHigh foot arches (pes cavus)Hammer toes or other foot deformitiesDifficulty lifting the front of the foot (foot drop)Numbness or reduced sensation in the feet and handsTingling or burning sensations in the limbsReduced ability to feel pain, heat, or coldWeakness in the hands and forearms in later stagesBalance problems and frequent tripping or fallingReduced or absent reflexes at the ankles and kneesFatigue with walking or physical activityScoliosis (curved spine) in some casesMild hearing loss in some genetic subtypes

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

3 events
Mar 2026The Effect of Local Corticosteroid Injection in Carpal Tunnel Syndrome Patients With Type 2 Diabetes

Haydarpasa Numune Training and Research Hospital

TrialNOT YET RECRUITING
May 2010Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

University of Iowa

TrialRECRUITING
Apr 2010Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

Michael Shy

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Autosomal dominant Charcot-Marie-Tooth disease type 2.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
Other2 trials
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
Actively Recruiting
PI: Michael E Shy, MD (University of Iowa) · Sites: Los Angeles, California; Palo Alto, California +20 more
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
Actively Recruiting
PI: Michael E Shy, MD (University of Iowa) · Sites: Los Angeles, California; Palo Alto, California +20 more

Specialists

2 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Autosomal dominant Charcot-Marie-Tooth disease type 2.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Autosomal dominant Charcot-Marie-Tooth disease type 2Forum →

No community posts yet. Be the first to share your experience with Autosomal dominant Charcot-Marie-Tooth disease type 2.

Start the conversation →

Latest news about Autosomal dominant Charcot-Marie-Tooth disease type 2

Disease timeline:

New recruiting trial: Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

A new clinical trial is recruiting patients for Autosomal dominant Charcot-Marie-Tooth disease type 2

New recruiting trial: Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

A new clinical trial is recruiting patients for Autosomal dominant Charcot-Marie-Tooth disease type 2

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific gene is causing my CMT2, and how does that affect my expected disease course?,How quickly is my condition likely to progress, and what signs should I watch for?,What therapies or exercises are most helpful for my current level of symptoms?,Should my children or other family members be tested for this condition?,Are there any clinical trials I might be eligible for?,What specialists should be part of my care team, and how often should I be seen?,Are there any medications or activities I should avoid that could worsen nerve damage?

Common questions about Autosomal dominant Charcot-Marie-Tooth disease type 2

What is Autosomal dominant Charcot-Marie-Tooth disease type 2?

Autosomal dominant Charcot-Marie-Tooth disease type 2 (also called CMT2 or hereditary motor and sensory neuropathy type 2, HMSN II) is a inherited nerve disease that affects the peripheral nervous system — the nerves outside the brain and spinal cord. Unlike the more common CMT type 1, which damages the protective myelin sheath around nerves, CMT2 directly damages the nerve fibers themselves (called axons). This means signals between the brain and the muscles and skin travel poorly or not at all. The disease mainly affects the legs and arms, causing muscle weakness and wasting, especially in

How is Autosomal dominant Charcot-Marie-Tooth disease type 2 inherited?

Autosomal dominant Charcot-Marie-Tooth disease type 2 follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Autosomal dominant Charcot-Marie-Tooth disease type 2?

Yes — 2 recruiting clinical trials are currently listed for Autosomal dominant Charcot-Marie-Tooth disease type 2 on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Autosomal dominant Charcot-Marie-Tooth disease type 2?

2 specialists and care centers treating Autosomal dominant Charcot-Marie-Tooth disease type 2 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.